Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational trial of narazaciclib for the treatment of low grade endometrioid endometrial cancer (LGEEC)

Trial Profile

A registrational trial of narazaciclib for the treatment of low grade endometrioid endometrial cancer (LGEEC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narazaciclib (Primary)
  • Indications Endometrial cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
  • 21 Nov 2023 New trial record
  • 14 Nov 2023 According to an Onconova Therapeutics media release, the company provides an update on our registrational trial-readiness over the next few quarters, including the definition of our recommended Phase 2 dose, engagement with the FDA on the pivotal trial design, and continuing to work with external clinical experts including the Gynecologic Oncology Group (GOG), and the European Network for Gynecologic Oncology Trials (ENGOT).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top